The standard treatment for acute respiratory failure in critically ill patients has been based on oxygen therapy and invasive mechanical ventilation with endotracheal intubation. In addition, non-invasive mechanical ventilation (NIV) has proved an excellent technique, avoiding the need for intubation and improving outcome in selected patients with acute cardiogenic pulmonary edema, exacerbation of chronic obstructive pulmonary disease (COPD), and acute hypoxemic respiratory failure \[[@B1]-[@B4]\]. Conversely to invasive mechanical ventilation, NIV can also be used outside the intensive care unit \[[@B5]\]. However, NIV can fail because of either the patient\'s underlying conditions or multiple technical causes. Despite improvements in the oro-nasal mask\'s characteristics, intolerance to the device represents a frequent cause of failure \[[@B6]\]; thus, the interface is fundamental in the care of patients. One possible alternative to the face mask could be the helmet, especially for long-term use (Figure [1](#F1){ref-type="fig"}). Although the facial mask is still the most commonly used interface in up to 60% of cases, in some European countries (such as Italy), the helmet is widely employed for patients with acute hypoxemic respiratory failure and acute cardiogenic pulmonary edema \[[@B6]\].

![**Non-invasive ventilation and helmet in use on a patient with acute respiratory syndrome in the ICU**.](cc11875-1){#F1}

The aim of this clinical review is to summarize the main physiological and clinical studies assessing the efficacy (arterial oxygenation, intubation rate, outcome and tolerance) of NIV delivered with the helmet.

Methods
=======

Search strategy
---------------

A computerized search of MEDLINE/PubMed (January 2000 to May 2012) and EMBASE (January 2000 to May 2012) for articles in English, Spanish and Italian was conducted, limiting the search to retrospective, prospective, non-randomized and randomized trials. The keywords \'noninvasive ventilation\', \'helmet\' and \'interface\' were combined with any of the terms \'chronic obstructive pulmonary disease\', \'hypoxemic acute respiratory failure\', \'continuous positive airway pressure\', \'bi-level airway pressure\' and \'pressure support ventilation\'. The biographies of all selected articles were hand searched for additional relevant articles.

Five international experts participated and conducted this analysis (AE, PP, MC, RC, DC) and classified the results into two major groups: physiological and clinical studies.

Results
=======

In the text the data are expressed as mean ± standard deviation. We analyzed 152 studies from which 33 were selected for this clinical review. Twelve of these were physiological studies, performed in healthy subjects, and 21 were clinical studies, performed in patients with acute respiratory failure (Figure [2](#F2){ref-type="fig"}). Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarize the main results.

![**Flow chart of the studies analyzed**. NIV, non-invasive ventilation.](cc11875-2){#F2}

###### 

Summary of the physiological studies

  Source                                 Type of non-invasive ventilation                        Number of subjects   Interface                                       Control   Results
  -------------------------------------- ------------------------------------------------------- -------------------- ----------------------------------------------- --------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Patroniti *et al*. (2003) \[[@B7]\]    CPAP                                                    8                    Helmet                                          FM        Higher CO~2~rebreathing with helmet
  Taccone *et al*. (2004) \[[@B8]\]      CPAP                                                    8                    Helmet                                          FM        Higher CO~2~rebreathing with helmet
  Patroniti *et al*. (2007) \[[@B9]\]    CPAP                                                    5                    Helmet with and without antisuffocation valve   \-        CO~2~rebreathing limited by safety valve
  Milan *et al*. (2011) \[[@B10]\]       CPAP                                                    5                    Helmet with antisuffocation valve               \-        CO~2~rebreathing decreased by a higher diameter of safety valve
  Costa *et al*. (2005) \[[@B11]\]       PSV                                                     8                    Helmet                                          \-        CO~2~rebreathing not affected by PEEP on PSV level; inspiratory effort decreased, increasing the PSV
  Racca *et al*. (2008) \[[@B13]\]       PSV - CPAP                                              10                   Helmet                                          \-        Lower CO~2~rebreathing with open circuit mechanical ventilators
  Chiumello *et al*. (2003) \[[@B14]\]   PSV - CPAP                                              6                    Helmet                                          FM        Similar breathing pattern and WOB during CPAP, higher reduction of WOB during PSV with FM
  Racca *et al*. (2005) \[[@B12]\]       PSV                                                     6                    Helmet                                          FM        Higher CO~2~rebreathing, inspiratory effort, autocycled breaths and dyspnea score with helmet during respiratory muscle load
  Costa *et al*. (2010) \[[@B19]\]       PSV different inspiratory-expiratory cycling criteria   8                    Helmet                                          FM        Shorter ventilator inspiratory time and longer with inspiratory-expiratory delay with helmet. The fast setting ameliorated patient-ventilator interaction
  Moerer *et al*. (2008) \[[@B21]\]      PSV pneumatically versus neutrally triggered            7                    Helmet                                          \-        Shorter inspiratory-expiratory delays, lower wasted efforts and better comfort with neurally triggered PSV
  Chiumello *et al*. (2008) \[[@B24]\]   CPAP                                                    10                   Helmet                                          \-        Higher temperature and humidity of inspired gas compared to un-humidified medical gases
  Cavaliere *et al*. (2003) \[[@B25]\]   PSV                                                     10                   Helmet                                          FM        Higher acoustic compliance with Helmet

CO~2~, carbon dioxide; CPAP, continuous positive airway pressure; FM, face mask; PSV, pressure-support ventilation; WOB, work of breathing.

###### 

Summary of the clinical studies

  Source                                           Study design                        Inclusion criteria                              Enrolled patients   Type of non-invasive ventilation      Interface   Control           Arterial oxygenation                                         Intubation rate     Outcome                Tolerance
  ------------------------------------------------ ----------------------------------- ----------------------------------------------- ------------------- ------------------------------------- ----------- ----------------- ------------------------------------------------------------ ------------------- ---------------------- ---------------------------------------------------------
  Foti *et al*. (2009) \[[@B28]\]                  Observational                       Presumed acute cardiogenic pulmonary edema      121                 CPAP                                  Helmet      O~2~therapy       Higher with helmet                                           No data             No data                No difference
  Tonnelier *et al*. (2003) \[[@B29]\]             Prospective with matched control    Acute cardiogenic pulmonary edema               11                  CPAP                                  Helmet      FM                No difference                                                No data             No data                No difference
  Antonelli *et al*. (2002) \[[@B32]\]             Prospective with matched control    Hypoxemic ARF                                   33                  PSV                                   Helmet      FM                Higher with FM                                               No difference       No difference          Higher intolerance in FM versus helmet (38% versus 0%)
  Cammarota *et al*. (2011) \[[@B36]\]             Cross-over                          Hypoxemic ARF                                   24                  CPAP with or without sigh             Helmet      Venturi mask      Higher during sigh in bilateral lung involvement             No data             No data                No difference
  Isgrò *et al*. (2010) \[[@B37]\]                 Cross-over                          Hypoxemic ARF                                   21                  CPAP with or without sigh and BIPAP   Helmet      \-                Higher oxygenation during sigh and BIPAP                     No data             No data                Similar tolerance
  Cammarota *et al*. (2011) \[[@B38]\]             Cross-over                          Post-extubation ARF                             10                  PSV - NAVA                            Helmet      \-                No difference                                                No difference       No difference          No data
  Principi *et al*. (2004) \[[@B41]\]              Prospective with historical group   Hematological malignancy with hypoxemic ARF     17                  CPAP                                  Helmet      FM                No difference                                                Favor helmet        Favor helmet           Higher intolerance in FM versus helmet (11% versus 0%)
  Rocco *et al*. (2004) \[[@B42]\]                 Matched-control group               Immunocompromised patients with hypoxemic ARF   19                  PSV                                   Helmet      FM                No difference                                                No difference       No difference          Higher intolerance in FM versus helmet (47% versus 10%)
  Rabitsch *et al*. (2003) \[[@B43]\]              Prospective observational           Immunocompromised patients with hypoxemic ARF   10                  PSV                                   Helmet      \-                Increased                                                    20%                 No data                No data
  Carron *et al*. (2010) \[[@B45]\]                Prospective observational           Hypoxemic ARF                                   67                  PSV                                   Helmet      \-                Lower in NIV failure                                         56%                 Lower in NIV failure   No data
  Cosentini *et al*. (2010) \[[@B46]\]             Randomized controlled               Hypoxemic ARF                                   47                  CPAP                                  Helmet      O~2~therapy       Higher in helmet                                             No difference       No difference          No difference
  Belenguer-Muncharaz *et al*. (2011) \[[@B49]\]   Retrospective observational         Hypoxemic ARF due to influenza H1N1             5                   CPAP - PSV                            Helmet      Boussignac - FM   No difference                                                0%                  100% alive             No data
  Squadrone *et al*. (2005) \[[@B53]\]             Randomized controlled unblinded     Postoperative patients with acute hypoxemia     209                 CPAP                                  Helmet      O~2~therapy       Higher with helmet                                           Favor helmet        No difference          No difference
  Conti *et al*. (2007) \[[@B54]\]                 Matched-control                     Postoperative ARF                               25                  PSV                                   Helmet      FM                No difference                                                Favor helmet        No difference          Higher intolerance in FM versus helmet(32% versus 12%)
  Redondo Calvo *et al*. (2012) \[[@B55]\]         Prospective observational           Postoperative patients with hypoxemia           99                  CPAP                                  Helmet      \-                Increased                                                    25%                 No data                No data
  Barbagallo *et al*. (2012) \[[@B56]\]            Randomized unblinded                Postoperative thoracic surgery                  50                  CPAP                                  Helmet      O~2~therapy       Higher with helmet                                           No difference       No difference          No data
  Antonelli *et al*. (2004) \[[@B57]\]             Case-control                        Acute exacerbation of COPD                      33                  PSV                                   Helmet      FM                Similar oxygenation but lower CO~2~improvement with helmet   No difference       No difference          Higher intolerance in FM versus helmet (36% versus 0%)
  Antonaglia *et al*. (2011) \[[@B58]\]            Randomized controlled               Acute exacerbation of COPD                      53                  PSV                                   Helmet      FM                Similar oxygenation but lower CO~2~improvement with helmet   Lower with helmet   No difference          Higher intolerance in FM versus helmet (40% versus 5%)
  Navalesi *et al*. (2007) \[[@B59]\]              Randomized cross-over               Acute exacerbation of COPD                      10                  PSV                                   Helmet      FM                No difference                                                No difference       No difference          No difference
  Vargas *et al*. (2009) \[[@B60]\]                Cross-over                          Post-extubation ARF                             11                  PSV                                   Helmet      FM                No data                                                      No data             No data                No difference
  Antonelli *et al*. (2003) \[[@B62]\]             Prospective observational           ARF requiring FOB                               4                   PSV                                   Helmet      \-                No change                                                    No data             No data                No data
  Rocco *et al*. (2010) \[[@B65]\]                 Prospective observational           ARF that required NIV interruption              36                  PSV                                   Helmet      FM                No change                                                    39%                 28%                    No difference

ARF, acute respiratory failure; BIPAP, bi-level positive airway pressure; CO~2~, carbon dioxide; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; FM, face mask; FOB, fiberoptic bronchoscopy; NAVA, neurally adjusted ventilatory assist; O~2~, oxygen; PSV, pressure-support ventilation.

Physiological studies
---------------------

### Carbon dioxide rebreathing

Compared to the face mask the helmet, due to its larger internal volume, might facilitate carbon dioxide (CO~2~) rebreathing. Patroniti and colleagues \[[@B7]\] found that, with continuous flow continuous positive airway pressure (CPAP) and a gas flow from 20 to 60 L/minute and positive end-expiratory pressure (PEEP) from 0 to 15 cmH~2~O, the inspiratory CO~2~concentration was always higher with the helmet than with the face mask (3.1 ± 0.15 versus 0.8 ± 0.3 mmHg, *P*\< 0.01). Increasing the gas flow rate significantly lowered the inspiratory CO~2~concentration.

Similarly, Taccone and colleagues \[[@B8]\] observed that the CO~2~concentration was similar between a continuous low flow CPAP (10 L/minute) and CPAP delivered by a mechanical ventilator (13.7 ± 6.6 versus 12.4 ± 3.2 mmHg). In addition, reducing the size of the helmet did not prevent CO~2~rebreathing, suggesting that the CO~2~rebreathing primarly depends on the fresh gas passing through the helmet and the amount of CO~2~produced by the patient.

Among the commercially available helmets, CO~2~rebreathing was lower than 5 mmHg and not different during continuous high flow CPAP \[[@B9]\]. An antisuffocation valve, which allows room air to enter the helmet during any interruption of gas flow, limited the CO~2~rebreathing but not the loss of external PEEP \[[@B9]\]. In a subsequent study, Milan and colleagues \[[@B10]\], testing three commercially available helmets supplied with antisuffocation valves, found that the helmet with the largest valve had lower CO~2~rebreathing but a greater reduction in oxygenation in case of interruption of the gas flow.

Costa and colleagues \[[@B11]\] tested the helmet at different PSV and PEEP combinations and did not find any changes in CO~2~rebreathing, which ranged from 5.2 ± 3.1 to 6.7 ± 3.3 mmHg. However, during PSV of 5, 10 and 15 cmH~2~O with an increased respiratory muscle load, the helmet was always associated with more CO~2~rebreathing independent of the level of pressure support compared to the face mask (4.3 ± 0.5 versus 0.0 ± 0.0 mmHg, 3.5 ± 1.0 versus 0.4 ± 0.4 mmHg and 4.4 ± 1.3 mmHg versus 0.5 ± 0.6 mmHg; *P*\< 0.0001) \[[@B12]\].

Racca and colleagues \[[@B13]\] evaluated if an intentional leak at the helmet expiratory port during PSV, by increasing the flow through the helmet, could ameliorate the CO~2~rebreathing. NIV and CPAP were delivered using closed and open circuit ventilators equipped with a plateau valve positioned at the helmet\'s expiratory port. CO~2~rebreathing was significantly lower with the open-circuit ventilators. However, inspiratory pressure assistance significantly dropped with these open-circuit ventilators, casting doubt on the choice of the optimal helmet ventilation setup.

### Breathing pattern, inspiratory effort and comfort

Besides the larger internal volume that affects CO~2~rebreathing, the higher compliance of the helmet might delay ventilator assistance and may promote patient-ventilator asynchrony.

Chiumello and colleagues \[[@B14]\] evaluated the breathing pattern and work of breathing (WOB) with helmet and face masks during continuous flow CPAP, mechanical ventilator CPAP and PSV. During continuous flow CPAP, mechanical ventilator CPAP and PSV there was no difference in breathing pattern and WOB; on the contrary, during PSV the face mask significantly reduced the WOB compared to the helmet. The helmet requires a significant portion of the ventilator pressure in the initial phase of inspiration to pressurize its inner volume and not the patient, resulting in less assistance (that is, it takes a longer time to reach the required level of pressure support).

In a subsequent study Costa and colleagues \[[@B11]\], raising the level of pressure support from 5 to 15 cmH~2~O, found that the respiratory rate and inspiratory effort with the helmet progressively decreased and tidal volume increased compared to spontaneous breathing. The highest level of pressure support (15 cmH~2~O) significantly increased the discomfort.

Racca and colleagues \[[@B12]\] compared the helmet and face mask during PSV with normal and high respiratory muscle load to mimic dyspneic patients. With normal muscle load the breathing pattern and inspiratory effort was not different with helmet and face mask, but with high respiratory muscle load the inspiratory effort was significantly higher with the helmet than with the face mask.

Helmet devices may predispose to auto-cycled phenomena. Its elastic properties thus predispose to flow variations not tracked by effective inspiratory or expiratory efforts. Autocycled breathing was more common with helmet ventilation - on average double that with face mask ventilation \[[@B12]\]. The dyspnea score was significantly higher with high respiratory muscle load with helmet compared to face mask ventilation \[[@B12]\].

### Patient ventilator synchrony

PSV, the most commonly used ventilatory support during NIV, is regulated by pneumatic triggering based on flow criteria. To improve patient ventilator synchrony, it is possible in most current mechanical ventilators to adjust the pressurization time and the expiratory cycling off criteria to better match the neural time with the ventilator time \[[@B15]-[@B18]\]. Costa and colleagues \[[@B19]\] examined the effects of different pressurization times and different expiratory cycling criteria during PSV delivered by helmet or face mask. The ventilator inspiratory time was significantly longer with the face mask compared to the helmet. The helmet presented a significantly longer inspiratory and shorter expiratory trigger delay. However, a shorter pressurization time compared to a longer or intermediate time resulted in a significant improvement in patient ventilator synchrony.

To ameliorate the asynchrony that can be present with conventional pneumatic ventilator triggering, neural triggering using diaphragm electrical activity has been developed \[[@B20]\]. Moerer and colleagues \[[@B21]\] compared neurally and pneumatically triggered PSV delivered with a helmet with regard to synchrony and patient comfort. The pneumatic trigger was delayed compared to the neural trigger and directly increased with the level of PSV; during pneumatic triggering the number of wasted efforts increased with high PSV, while wasted inspiratory efforts did not occur during neural triggering. The expiratory delay was always lower with pneumatic compared to neural triggering. Comfort of breathing was also lower during pneumatic triggering compared to neural triggering.

### Humidity and noise

Although the optimal level of humidification of inspired gases during NIV is unknown, inadequate humidification can cause patient distress and favour intolerance \[[@B1],[@B22],[@B23]\]. Similar to CO~2~rebreathing related to the helmet\'s high internal volume, the humidity of expired gases can mix with the fresh inspired gases, which are more dry and cold, thus increasing the level of heat and humidity, avoiding the necessity of active humidification. Chiumello and colleagues \[[@B24]\] reported that during continuous flow CPAP without an active humidifier, the temperature and humidity levels of the inspired gases were significantly higher compared to non-humidified medical gases and they were directly dependent on the gas flow passing throught the helmet.

Compared to the face mask the helmet can expose the entire head to positive pressure, which may injure the tympanic membranes. Cavaliere and colleagues \[[@B25]\] evaluated the performance of the middle ear by recording the tympanometry and the acoustic reflex after one hour of PSV with both the helmet and the face mask. During PSV with the helmet, the tympanometry showed a slight increase in acoustic compliance but returned to basal values after one hour, while it did not show a change with the face mask. In both groups the acoustic reflex did not change. These data may suggest the use of ear plugs in selective cases, such as during long-term use and when high airway pressures are used.

Clinical studies
----------------

### Acute cardiogenic pulmonary edema

During acute pulmonary edema the main beneficial effects of NIV besides the improvement of gas exhange are the reduction of preload and afterload, which improves the cardiac performace \[[@B26],[@B27]\].

In an observational study of 121 patients with presumed acute pulmonary cardiogenic edema, Foti and colleagues \[[@B28]\], in a prehospital setting applying a continous flow CPAP with a helmet, found a significant improvement in arterial oxygen saturation (79 ± 12% versus 97 ± 3%, *P*\< 0.01) and in hemodynamics (systolic blood pressure 175 ± 49 mmHg versus 145 ± 28 mmHg, *P*\< 0.01). The helmet CPAP was well tolerated in all enrolled patients.

In a prospective pilot study with a matched control group of patients with hypoxemic acute respiratory failure related to cardiogenic pulmonary edema, Tonnelier and colleagues \[[@B29]\] reported that helmet CPAP significantly reduced respiratory rate and heart rate and improved oxygenation (158 ± 94 mmHg versus 145 ± 28 mmHg), similar to the mask. Control patients were selected from a group of patients with acute respiratory failure due to cardiogenic pulmonary edema treated with a facial mask. The helmet allowed a longer period of CPAP without any adverse event and good tolerance.

### Hypoxemic acute respiratory failure

In a large multicenter survey of patients with hypoxemic acute respiratory failure, NIV was successful in avoiding intubation in 70% of the patients \[[@B30]\]. Patients with a high severity score (simplified acute physiology score (SAPS) II \>34), older age, acute respiratory distress syndrome or pneumonia, severe metabolic acidosis, severe hypoxemia (partial pressure of oxygen in arterial blood (PaO~2~)/fraction of inspired oxygen (FiO~2~) \<170) or failure in improvement in PaO~2~/FiO~2~after one hour of treatment were at higher risk of failure \[[@B31]\].

In a matched control study, Antonelli and colleagues \[[@B32]\] evaluated the efficiency of PSV delivered by helmet or face mask in patients with hypoxemic acute respiratory failure. Both groups had a similar improvement in oxygenation within the first hour; however, at support discontinuation the increase in oxygenation was higher for patients who received PSV by helmet (267 ± 104 mmHg versus 224 ± 81 mmHg, *P*\< 0.05). The total duration of PSV was similar (40 ± 30 hours versus 42 ± 31 hours), as well as the intubation rate and hospital mortality. No patients in the helmet group compared to 38% of the mask group had intolerance to NIV.

The application of periodic deep insufflation (sighs) during invasive mechanical ventilation may improve gas exchange \[[@B33]-[@B35]\]. In a prospective cross-over study, Cammarota and colleagues \[[@B36]\] found that during CPAP with either the helmet or face mask, the sigh (that is, an increase of airway pressure from 10 to 20 cmH~2~O for 8 seconds every minute) significantly improved the arterial oxygenation and reduced the respiratory rate. Independent of sigh, the helmet CPAP group had higher oxygenation while the tolerance was similar in the two groups.

Similarly to the previous study \[[@B36]\], in hypoxemic acute respiratory failure Isgrò and colleagues \[[@B37]\], applying a periodic sigh or two CPAP levels (similar to bi-level positive airway pressure (BIPAP) ventilation) during continuous flow CPAP with a helmet, found a significant improvement in oxygenation compared to basal CPAP (109.2 ± 33.9 mmHg versus 124.5 ± 45.2 mmHg and 128 ± 52 mmHg). There was no significant difference between sigh and BIPAP regarding oxygenation levels.

Compared to PSV, neurally adjusted ventilatory assist (NAVA) improved ventilator synchrony in healthy subjects \[[@B21]\]. Cammarota and colleagues \[[@B38]\] evaluated the short-term physiologic effects of NAVA compared to PSV delivered with helmet in postextubation acute respiratory failure. NAVA significantly increased the ventilator inspiratory and reduced expiratory time. No asynchrony was present with NAVA, while there were no differences in gas exchange and respiratory rate.

### Immunocompromised patients

The respiratory complications in immuncompromised patients remain the main cause of morbidity and mortality; thus, respiratory support that avoids or reduces pulmonary complications could be useful \[[@B39],[@B40]\].

Principi and colleagues \[[@B41]\], in a prospective clinical study of hematological malignancy patients with hypoxemic acute respiratory failure compared to historical matched controls, observed that no patient failed helmet CPAP due to intolerance of the technique compared to 11.4% of patients in the mask group, and that helmet CPAP could be applied continuously over a much longer period of time than mask CPAP (28.4 ± 0.2 hours versus 7.5 ± 0.4 hours, *P*\< 0.001). The oxygenation improvement was equal in the two groups but the intubation and mortality rates were lower with the helmet (0 versus 41% and 23 versus 47%, *P*\< 0.001).

Rocco and colleagues \[[@B42]\], in a matched controlled study of immunocompromised patients of different etiologies of acute respiratory failure, showed that patients receiving PSV with helmet had significantly lower NIV discontinuations in the first 24 hours than patients treated with mask; also, fewer complications related to device were reported (that is, skin necrosis, *P*= 0.01). Oxygenation, intubation and mortality rates were similar (202 ± 61 mmHg versus 224 ± 111 mmHg, 37% versus 47%, and 47% versus 31%, respectively).

In an observational study of immunocompromised patients with acute respiratory failure, Rabitsch and colleagues \[[@B43]\] reported that helmet PSV significantly improved arterial oxygenation and respiratory rate, and only two patients (20%) were intubated.

### Community-acquired pneumonia

Severe community-aquired pneumonia with intensive care admission and associated hypoxemic acute respiratory failure can require respiratory support in up of 60% of patients \[[@B44]\]. Carron and colleagues \[[@B45]\], in a prospective observational study including 64 consecutive patients with acute respiratory failure due to community-aquired pneumonia, investigated the failure of NIV. NIV was delivered as PSV with helmet. It was found that NIV succeeded in 43% of patients and failed in 56%. The only two independent factors associated with failure were changes in arterial oxygenation and oxygenation index between admission and after 1 hour of NIV.

In a large multicenter randomized controlled trial in patients with hypoxemic acute respiratory failure due to community-aquired pneumonia, Cosentini and colleagues \[[@B46]\] compared continuous flow CPAP delivered by helmet and oxygen therapy for improving oxygenation. The primary end point was the time required to reach a PaO~2~/FiO~2~ratio above 315 mmHg. This was reached in a significantly shorter time in the helmet group compared to the control group (1.5 hours versus 48 hours, *P*\< 0.001). In the helmet group 95% of patients reached this end point compared to 30% of the controls (*P*\< 0.001). No patients required intubation or died during the study.

In the last recent pandemic due to influenza A (H1N1) it was reported that patients admitted to intensive care for acute respiratory failure with severe hypoxemia required respiratory support in up of 80% of cases \[[@B47],[@B48]\]. A retrospective observational study evaluated the use of NIV in all patients admitted to intensive care with presumed or confirmed influenza A (H1N1) infection and hypoxemic acute respiratory failure \[[@B49]\]. NIV was delivered as CPAP and PSV with a helmet or face mask. There was a significant improvement in gas exchange and respiratory and heart rates decreased. None of the patients required orotracheal intubation (100% success) and all the patients survived.

### Postoperative surgery

Postoperative complications, which include atelectasis, pulmonary edema, postoperative pneumonia and acute respiratory failure, arise in 5% to 10% of all surgical patients and significantly increase morbidity and mortality \[[@B1],[@B50]-[@B52]\].

In a randomized, controlled, unblinded study, Squadrone and colleagues \[[@B53]\] showed that postoperative patients who developed hypoxemia and received helmet CPAP compared to those treated with oxygen alone had a better oxygenation and a lower intubation rate (1% versus 10%, *P*= 0.005). The helmet group had a lower rate of pneumonia (2% versus 10%, *P*= 0.02), infection (3% versus 10%, *P*= 0.03), and sepsis (2% versus 9%, *P*= 0.03), and spent fewer days in the ICU (1.4 ± 1.6 versus 2.6 ± 4.2, *P*= 0.09) without any difference in the hospital length of stay (15 ± 13 versus 17 ± 15, *P*= 0.10).

In a matched-control study, Conti and colleagues \[[@B54]\] also found that in patients with acute respiratory failure after major abdominal surgery, PSV delivered by a helmet significantly improved oxygenation and reduced intubation rate (20% versus 48%, *P*= 0.036) compared to PSV with facial mask. The complications (mask intolerance, major leaks and ventilator-associated pneumonia) were significantly lower in the helmet group compared to the face mask group (12% versus 32%, *P*= 0.06).

In a prospective observational study evaluating helmet CPAP in postoperative patients who developed acute hypoxemic respiratory failure, Redondo-Calvo \[[@B55]\] and colleagues found that 74.7% of the patients did not require intubation. The intubated patients presented higher levels of illness and lower improvement in oxygenation and CPAP duration. The intubated patients had a longer hospital stay and higher rate of hospital deaths compared to unintubated (30.2 ± 20.1 days versus 12.7 ± 8.2 days, *P*\< 0.001, and 44% versus 15%, *P*= 0.004).

Although the NIV is commonly used to treat acute respiratory failure in postoperative patients, it has also been used to prevent acute respiratory complications after surgery \[[@B50]\]. Barbagallo and colleagues \[[@B56]\] randomized 50 patients after elective lung resection to a prophylactic continuous flow CPAP with helmet for two hours or to oxygen therapy. The helmet group had significantly higher oxygenation without any difference in postoperative complications and mortality.

### Hypercapnic acute respiratory failure

In COPD patients, NIV is recommended to improve gas exchange, and to decrease respiratory workload and the need for tracheal intubation \[[@B1],[@B4]\].

In a cohort study, Antonelli and colleagues \[[@B57]\] evaluated the effect of PSV delivered by helmet or by face mask on gas exchange and intubation rate in COPD patients with acute exacerbation. After one hour both groups presented a significant reduction of partial pressure of carbon dioxide in arterial blood (PaCO~2~) and improvement in pH. However, the decrease in PaCO~2~was lower in the helmet group compared to the face mask group (75 ± 15 mmHg versus 66 ± 15 mmHg, *P*= 0.01). Also, on discontinuing support, PaCO~2~was higher (*P*= 0.002) and pH lower (*P*= 0.02) in the helmet group. The improvements in oxygenation and respiratory rate were similar as well as the intubation rate (30% versus 42%). Intensive care and hospital mortality were not different between the groups.

Antonaglia and colleagues \[[@B58]\] ventilated a series of patients with severe exacerbation of COPD using PSV delivered by face mask for two hours; subsequently, only those in whom gas exchange improved were randomized to helmet or face mask. After four hours of NIV, the face mask group had a significantly lower PaCO~2~compared to the helmet group (63 ± 14 mmHg versus 70 ± 4 mmHg, *P*= 0.01) with no difference in oxygenation or respiratory rate. However, 9 of the 20 patients (45%) in the mask group compared to 2 of 20 (5%) in the helmet group required intubation (*P*\< 0.01).

In a small group of hypercapnic patients with severe COPD recovering from acute exacerbation, Navalesi and colleagues \[[@B59]\] evaluated PSV delivered by a helmet or face mask in random order. Compared to spontaneous breathing, NIV reduced PaCO~2~with both devices (from 55.9 ± 7.3 mmHg to 52.0 ± 7.1 mmHg with helmet, *P*\< 0.05; and from 55.5 ± 7.7 mmHg to 51.7 ± 8.5 mmHg with face mask, *P*\< 0.05). Ineffective inspiratory efforts were significantly more common with the helmet and although the WOB decreased to a similar extent as for spontaneous breathing, with the helmet the delay between inspiratory effort and ventilator support was significantly longer.

### Interfaces

In a prospective cross-over study Vargas and colleagues \[[@B60]\], in a group of patients at high risk for respiratory distress, compared three different NIV settings: PSV delivered by face mask; PSV at the same pressure support and PEEP with helmet; and PSV with 50% increases in pressure support and PEEP with helmet. At the same level of pressure support the helmet had a low inspiratory effort compared to face mask. The increase of PSV reduced the inspiratory effort to a similar extent as with the face mask. Patient ventilator asynchrony was more frequent with the helmet, while respiratory rate and patient comfort were similar among the three conditions.

### Novel indications

Arterial oxygenation lower than 75 mmHg with an oxygen fraction higher than 50% is considered a contraindication to fiberoptic bronchoscopy \[[@B61]\]. Antonelli and colleagues \[[@B62]\] investigated the feasibility and safety of fiberoptic bronchoscopy with bronchoalveolar lavage during NIV delivered with a helmet in patients with acute respiratory failure. Oxygenation did not change throughout the procedure and dropped only 2% at the end of the fiberoptic bronchoscopy. No patients required sedatives or analgesics.

### Sedation

Similar to invasive mechanical ventilation, sedation has been advocated to improve NIV tolerance and reduce the rate of failure \[[@B63],[@B64]\].

In a prospectively uncontrolled study, Rocco and colleagues \[[@B65]\] evaluated the continuous infusion of remifentanil in patients with hypoxemic acute respiratory failure during NIV with helmet or mask. The mean remifentanil dose administered was 0.07 ± 0.03 μg/kg/ minute and infusion lasted 52 ± 10 hours in the success group. Thirty-six patients were enrolled and 22 (61%) continued NIV treatment; after one hour respiratory rate decreased and oxygenation increased with both helmet and face mask. Fourteen patients failed (39%) and required endotracheal intubation because of persistence of discomfort.

Discussion
==========

In this review we identified, among the 33 studies considered, only 9 clinical studies in which the helmet was compared to face mask. The helmet presented similar oxygenation rates in eight \[[@B29],[@B41],[@B42],[@B49],[@B54],[@B57]-[@B59]\] and similar intubation rates in four \[[@B32],[@B42],[@B57],[@B59]\] of these compared to the face mask. The outcome was similar in six studies \[[@B32],[@B42],[@B54],[@B57]-[@B59]\]. The tolerance was better with helmet in six of these studies \[[@B58],[@B32],[@B57],[@B54],[@B41],[@B42]\].

The main application of NIV with helmet was for acute cardiogenic pulmonary edema, hypoxemic acute respiratory failure, community-acquired pneumonia, hypercapnic acute respiratory failure, and in post-operative and immunocompromised patients. The main favourable characteristics of the helmet (Table [3](#T3){ref-type="table"}), such as low distensibility, absence of any contact with the face, minimum presence of air leaks, the possibility to deliver continous flow CPAP as well as non-invasive positive pressure ventilation, can extend the application of NIV in patients with acute respiratory failure. However, the high internal volume can promote higher CO~2~rebreathing, patient ventilator asynchrony and lower reductions in WOB compared to the face mask. Higher levels of pressure support and faster pressurization rates, however, could improve the efficiency of the helmet to be comparable to the face mask. Table [4](#T4){ref-type="table"} summarizes general recommendations to optimize NIV with the helmet.

###### 

Major advantages and disvantages of the helmet

  Advantages                      Disadvantages
  ------------------------------- --------------------------------------------------
  Nutrition and hydration         Noise
  Lower air leaks                 Large dead space
  No facial skin lesions          Claustrophobia
  No eye irritation               Vascular complications
  Independent of the patient\'s   Skin lesions at the collar neck
  anatomy                         Desyncrhonization between patient and ventilator

###### 

Suggested key points for non-invasive ventilation delivered by helmet

  General recommendations
  ---------------------------------------------------------------------------------------------
  Use helmet in case of long duration non-invasive ventilation
  Use helmet in case of face skin lesions
  Use helmet in case of major air leaks
  Use helmet in edentulous patients
  Use helmet if mask intolerance
  Avoid CPAP delivered by mechanical ventilator
  Promote inter-change between helmet and face mask during long treatment
  Frequent assessment of gas exchange in the first hours
  Continuous flow CPAP
  Use inspiratory gas flow \>40 L/minute
  Pressure-support ventilation
  Apply higher PEEP and pressure support level (50% higher than those applied with face mask)
  Use the maximum pressurization rate

CPAP, continuous positive airway pressure; PEEP, positive end-expiratory pressure.

Conclusion
==========

The helmet has been shown to be an effective interface for the application of NIV, but compared to the face mask it may increase patient ventilator asynchrony and CO~2~rebreathing. However, the helmet is better tolerated, allowing longer use. Further studies are required to define the ideal patient populations and open up new clinical indications for NIV with the helmet.
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